2Andersen ME. Toxicokinetic modeling and its application in chemical risk assessment [J ]. Toxicol Lett, 2003, 138: 9-27.
3Clewell HJ 3rd, Andersen ME. Applying mode-of-action and phannacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene [J ]. Crit Rev Toxicol, 2004, 34: 385-445.
4USEPA. Approaches for the application of physiologically based pharmacokinetic(PBPK) models and supporting data in risk assessment [ OL ].http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid = 135427. 2005-07-28.
5Robert SD. PBPK models in risk assessment: a focus on chloroprene [J ]. Chem Biol Interact, 2007, 166:352-359.
6Rory BC. Biologically motivated quantitative models and the mixture toxicity problem[J ]. Toxicol Sci, 2001, 63:125-131.
7Weihsueh AC, Hugh AB, Robert SD, et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment [J ]. J Appl Toxicol, 2001, 63:218-237.
8Chao C, Robert DW. Improving risk assessment through the use of physiologieaUy-basedmodels [ OL ]. http://oaspub.epa.gov/eims/eimscomm. getfile?p_download_id=434178. 2007-09.
9USEPA. Toxicological review of xylenes [ OL ]. http://www.epa.gov/IRIS/ toxreviews/0270-tr.pdf. 2003-01.
10Clint AC, Barbara EH, James NM, et al. The effect of m-xylene on cytotoxicity and cellular antioxidant status in rat dermal equivalents [J ]. Toxicol Lett, 2003, 142: 133-142.
